APO Research

APO RESEARCH · REPORT

Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine

Selected research

Industry Research

Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Industry Research Report 2026

Market perspective

The global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine include Walvax Biotechnology, Sanofi, GSK, Sinopharm, Serum Institute of India and KM Biologics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market by Company

Walvax Biotechnology

Sanofi

GSK

Sinopharm

Serum Institute of India

KM Biologics

Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Segment by Type

DTaP

Tdap

Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Segment by Application

Child

Adult

Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales (k units) of Manufacturers (2021-2026) Table 7. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Manufacturers (2021-2026) Table 8. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue of Manufacturers (2021-2026) Table 9. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine, Product Type & Application Table 14. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Walvax Biotechnology Company Information Table 19. Walvax Biotechnology Business Overview Table 20. Walvax Biotechnology Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Walvax Biotechnology Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Product Portfolio Table 22. Walvax Biotechnology Recent Developments Table 23. Sanofi Company Information Table 24. Sanofi Business Overview Table 25. Sanofi Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Sanofi Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Product Portfolio Table 27. Sanofi Recent Developments Table 28. GSK Company Information Table 29. GSK Business Overview Table 30. GSK Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. GSK Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Product Portfolio Table 32. GSK Recent Developments Table 33. Sinopharm Company Information Table 34. Sinopharm Business Overview Table 35. Sinopharm Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Sinopharm Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Product Portfolio Table 37. Sinopharm Recent Developments Table 38. Serum Institute of India Company Information Table 39. Serum Institute of India Business Overview Table 40. Serum Institute of India Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Serum Institute of India Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Product Portfolio Table 42. Serum Institute of India Recent Developments Table 43. KM Biologics Company Information Table 44. KM Biologics Business Overview Table 45. KM Biologics Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. KM Biologics Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Product Portfolio Table 47. KM Biologics Recent Developments Table 48. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 49. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Region (2021-2026) & (k units) Table 50. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Region (2021-2026) Table 51. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Region (2027-2032) & (k units) Table 52. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Region (2027-2032) Table 53. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 54. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Region (2021-2026) Table 55. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 56. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Region (2027-2032) Table 57. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2021-2026) & (k units) Table 59. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2027-2032) & (k units) Table 60. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 61. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 62. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2021-2026) & (k units) Table 64. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2027-2032) & (k units) Table 65. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 66. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 67. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 68. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2021-2026) & (k units) Table 69. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2027-2032) & (k units) Table 70. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 71. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 72. South America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 73. South America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2021-2026) & (k units) Table 74. South America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2027-2032) & (k units) Table 75. South America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 76. South America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 77. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2021-2026) & (k units) Table 79. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2027-2032) & (k units) Table 80. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 81. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 82. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Type (2021-2026) & (k units) Table 83. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Type (2027-2032) & (k units) Table 84. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Type (2021-2026) Table 85. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Type (2027-2032) Table 86. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 87. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 88. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Type (2021-2026) Table 89. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Type (2027-2032) Table 90. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Price by Type (2021-2026) & (US$/unit) Table 91. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Price by Type (2027-2032) & (US$/unit) Table 92. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Application (2021-2026) & (k units) Table 93. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Application (2027-2032) & (k units) Table 94. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Application (2021-2026) Table 95. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Application (2027-2032) Table 96. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 97. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 98. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Application (2021-2026) Table 99. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Application (2027-2032) Table 100. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Price by Application (2021-2026) & (US$/unit) Table 101. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Price by Application (2027-2032) & (US$/unit) Table 102. Key Raw Materials Table 103. Raw Materials Key Suppliers Table 104. Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Distributors List Table 105. Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Customers List Table 106. Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Industry Trends Table 107. Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Industry Drivers Table 108. Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Industry Restraints Table 109. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Product Image Figure 5. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size (2021-2032) & (US$ Million) Figure 7. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales (2021-2032) & (k units) Figure 8. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Average Price (US$/unit) & (2021-2032) Figure 9. DTaP Product Image Figure 10. Tdap Product Image Figure 11. Child Product Image Figure 12. Adult Product Image Figure 13. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Share by Manufacturers in 2025 Figure 14. Global Manufacturers of Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine, Manufacturing Sites & Headquarters Figure 15. Global Top 5 and 10 Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Players Market Share by Revenue in 2025 Figure 16. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 18. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Region in 2025 Figure 19. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Region in 2025 Figure 20. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Country in 2025 Figure 21. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Country (2021-2032) Figure 22. North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Country (2021-2032) Figure 23. United States Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 24. Canada Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Mexico Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Country in 2025 Figure 27. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Country (2021-2032) Figure 28. Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Country (2021-2032) Figure 29. Germany Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. France Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. U.K. Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Italy Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Russia Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Spain Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Netherlands Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Switzerland Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Sweden Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Poland Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Country in 2025 Figure 40. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Country (2021-2032) Figure 41. Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Country (2021-2032) Figure 42. China Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Japan Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. South Korea Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. India Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Australia Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Taiwan Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Southeast Asia Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. South America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Country in 2025 Figure 51. South America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Country (2021-2032) Figure 52. South America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Country (2021-2032) Figure 53. Brazil Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Argentina Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Chile Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Country in 2025 Figure 57. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Country (2021-2032) Figure 58. Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Country (2021-2032) Figure 59. Egypt Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. South Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Israel Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Türkiye Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. GCC Countries Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Type (2021-2032) Figure 65. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Type (2021-2032) Figure 66. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Price (US$/unit) by Type (2021-2032) Figure 67. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Application (2021-2032) Figure 68. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Application (2021-2032) Figure 69. Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Price (US$/unit) by Application (2021-2032) Figure 70. Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Value Chain Figure 71. Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Industry Opportunities and Challenges

Scope & coverage.

Types
  • DTaP
  • Tdap
Applications
  • Child
  • Adult
Companies covered
  • Walvax Biotechnology
  • Sanofi
  • GSK
  • Sinopharm
  • Serum Institute of India
  • KM Biologics

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size (2021-2032)
  4. 2.2.2 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales (2021-2032)
  5. 2.2.3 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Average Price (2021-2032)
  6. 2.3 Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 DTaP
  9. 2.3.3 Tdap
  10. 2.4 Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Child
  13. 2.4.3 Adult
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine, Product Type & Application
  8. 3.8 Global Manufacturers of Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine, Established Date
  9. 3.9 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Walvax Biotechnology
  2. 4.1.1 Walvax Biotechnology Company Information
  3. 4.1.2 Walvax Biotechnology Business Overview
  4. 4.1.3 Walvax Biotechnology Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Walvax Biotechnology Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Product Portfolio
  6. 4.1.5 Walvax Biotechnology Recent Developments
  7. 4.2 Sanofi
  8. 4.2.1 Sanofi Company Information
  9. 4.2.2 Sanofi Business Overview
  10. 4.2.3 Sanofi Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Sanofi Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Product Portfolio
  12. 4.2.5 Sanofi Recent Developments
  13. 4.3 GSK
  14. 4.3.1 GSK Company Information
  15. 4.3.2 GSK Business Overview
  16. 4.3.3 GSK Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 GSK Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Product Portfolio
  18. 4.3.5 GSK Recent Developments
  19. 4.4 Sinopharm
  20. 4.4.1 Sinopharm Company Information
  21. 4.4.2 Sinopharm Business Overview
  22. 4.4.3 Sinopharm Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Sinopharm Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Product Portfolio
  24. 4.4.5 Sinopharm Recent Developments
  25. 4.5 Serum Institute of India
  26. 4.5.1 Serum Institute of India Company Information
  27. 4.5.2 Serum Institute of India Business Overview
  28. 4.5.3 Serum Institute of India Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Serum Institute of India Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Product Portfolio
  30. 4.5.5 Serum Institute of India Recent Developments
  31. 4.6 KM Biologics
  32. 4.6.1 KM Biologics Company Information
  33. 4.6.2 KM Biologics Business Overview
  34. 4.6.3 KM Biologics Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 KM Biologics Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Product Portfolio
  36. 4.6.5 KM Biologics Recent Developments
5 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Scenario by Region
  1. 5.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Region: 2021-2032
  3. 5.2.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Region: 2021-2026
  4. 5.2.2 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Region: 2027-2032
  5. 5.3 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Region: 2021-2032
  6. 5.3.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Region: 2021-2026
  7. 5.3.2 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Region: 2027-2032
  8. 5.4 North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Facts & Figures by Country
  9. 5.4.1 North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2021-2032)
  11. 5.4.3 North America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Facts & Figures by Country
  16. 5.5.1 Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2021-2032)
  18. 5.5.3 Europe Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Facts & Figures by Country
  41. 5.7.1 South America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2021-2032)
  43. 5.7.3 South America Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Type (2021-2032)
  2. 6.1.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Type (2021-2032)
  4. 6.2 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Type (2021-2032)
  5. 6.2.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Application (2021-2032)
  2. 7.1.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Market Share by Application (2021-2032)
  4. 7.2 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue by Application (2021-2032)
  5. 7.2.1 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Value Chain Analysis
  2. 8.1.1 Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Production Mode & Process
  5. 8.2 Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Distributors
  8. 8.2.3 Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Customers
9 Global Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Analyzing Market Dynamics
  1. 9.1 Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Industry Trends
  2. 9.2 Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Industry Drivers
  3. 9.3 Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Industry Opportunities and Challenges
  4. 9.4 Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research